Q-omics provides the consensus-scored ZNF311 profile across patient tissues and cancer cell-line models. ZNF311 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in UCS. Among the 18 cancer types available for tumor–normal comparison, ZNF311 is differentially expressed in 10, with the highest sampling consensus in COAD. Additionally, ZNF311 RNA expression shows 18,706 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight UCS, COAD, and UVM as cancer lineages where ZNF311 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ZNF311 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ZNF311 survival associations across molecular data types. ZNF311 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ZNF311 RNA expression–survival associations across cancer types. High ZNF311 expression shows unfavorable associations in LGG and UCEC, but favorable associations in UCS, READ, BRCA and GBM. The UCS Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify UCS as the clearest survival context for ZNF311 RNA expression.
This table summarizes ZNF311 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10, while mass-spec protein shows differences in 1. The strongest signals are observed in COAD for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for ZNF311. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ZNF311 shows lower tumor expression in THCA, UCEC and KICH and higher tumor expression in COAD, HNSC and READ. The COAD box plot shows higher ZNF311 RNA expression in tumor versus normal tissue (log2 FC = +0.504, t-test p < 0.001).
This table shows molecular features associated with ZNF311 in patient tissues and cancer cell lines. In patient samples, ZNF311 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, ZNF311 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in KIDNEY, while CRISPR and shRNA rows add functional-dependency signals in OVARY and BLOOD_Leukemia.
